The Rationale: Last Reported Quarter and Management Outlook for Oncolytics Biotech Inc. (NASDAQ:ONCY)
Key Highlights12.2 million USD is theRevenueAntalpha PlatformHolding Company(NASDAQ:ANTA) reported for the second quarter of 2026, down 28% from a year earlier, led by USD 7.7 million of technology financing fees.10 million to USD 12 million is the revenue range management guided for the third …
The Rationale: Last Reported Quarter and Management Outlook for GameSquare Holdings, Inc. (NASDAQ:GAME)
Second quarterGross Profitwas USD 1.98 million, an 87% margin, compared with a gross deficit of about USD 0.3 million, or about -46%, in the second quarter of 2025. Operating expenses fell to USD 3.6 million from USD 4.3 million, and management cited annualized operating …
The Rationale: Last Reported Quarter and Management Outlook for Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)
Second quarter gross profit was USD 551 thousand at a 69.0% margin, versus USD 190 thousand and 41.8% a year earlier. The operating loss was USD 6.0 million versus USD 4.3 million, the net loss was USD 5.2 million versus USD 3.1 million, and …
In the second quarter of 2026 management reported that 2.5-year overall survival was 75% versus 47%, and that the European Medicines Agency and Australia'sTherapeutic Goods Administrationaligned on 3-year overall survival and biomarker data as approvable measures. Phase 3 design alignment was reached among the …
Second quarter gross margin was USD 1.2 million, or 15.0%, versus 3.8% a year earlier, while operating expenses rose 8.9% to USD 13.5 million. Adjusted EBITDA loss was USD 10.3 million versus USD 10.1 million. The company placed 4 Growth Direct systems and completed …
The quarter was shaped by regulatory events involving ARD-101, the company's lead candidate for Prader-Willi syndrome. In May 2026 the FDA placed a full clinical hold on the ARD-101 IND following a voluntary pause, and in June 2026 the company terminated the HERO Phase …
Operating expenses were USD 11.9 million in the second quarter, comprising SG&A of USD 7.8 million and R&D of USD 4.1 million. First-half sales were USD 7.9 million versus pro forma USD 8.2 million, and the first-half net loss was USD 40.1 million, or …